Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398956 | 0.86 | TDP1 (0.44) | TSHRTDP1CTRB1FASNMMP9 | |
| SCHEMBL17512439 | 0.84 | CALM1 (0.39) | CTRB1FASNMMP9GRM2GBA1 | |
| SCHEMBL16398868 | 0.84 | TP53 (0.41) | CTRB1FASN | |
| SCHEMBL699638 | 0.82 | CTRB1 (0.33) | CTRB1FASNGRM2GBA1F2 | |
| SCHEMBL1698739 | 0.81 | AKR1B1 (0.46) | TSHRCTRB1LTB4RLTB4R2 | |
| SCHEMBL3696640 | 0.80 | TRPA1 (0.39) | — | |
| SCHEMBL3699551 | 0.80 | TRPA1 (0.39) | — | |
| SCHEMBL2785355 | 0.80 | TRPA1 (0.39) | — | |
| SCHEMBL3392333 | 0.79 | FASN (0.34) | CTRB1FASN | |
| SCHEMBL632476 | 0.79 | HTR2A (0.44) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112584-B2 | Nonsteroidal antiinflammatory agents | SCHERING AG (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-1572671-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | SCHERIN AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004058733-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES | TSHR 3390/4885TDP1 1344/4885CTRB1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.